Literature DB >> 17023089

Inhaled cytokines and cytokine antagonists.

John Thipphawong1.   

Abstract

Cytokine and cytokine antagonist have provided novel and effective therapies for many human diseases. A number of approved cytokines including the interferons (alpha, beta and gamma), interleukin-2 (IL-2), granulocyte macrophage colony stimulating factor (GM-CSF) as well as novel cytokine antagonists have been administered by the pulmonary route for both local lung disease and as a non-invasive method for systemic delivery. We review the published clinical experience of inhaled cytokines and cytokine antagonists. We discuss the limitations of the existing data and the type of clinical data desired to establish the advantages and safety of inhaled cytokines and cytokine antagonists.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023089     DOI: 10.1016/j.addr.2006.07.014

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  3 in total

1.  Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serum.

Authors:  Li Xue; Rasheeda Johnson; Boris Gorovits
Journal:  AAPS J       Date:  2009-12-15       Impact factor: 4.009

2.  Effect of formulation on the stability and aerosol performance of a nebulized antibody.

Authors:  Renaud Respaud; Denis Marchand; Christelle Parent; Thibaut Pelat; Philippe Thullier; Jean-François Tournamille; Marie-Claude Viaud-Massuard; Patrice Diot; Mustapha Si-Tahar; Laurent Vecellio; Nathalie Heuzé-Vourc'h
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

Review 3.  Are inhaled systemic therapies a viable option for the treatment of the elderly patient?

Authors:  Stephen Allen
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.